Last time we looked, Turing Pharmaceutical honcho Martin Shkreli was busy reneging on his company’s promise to drastically reduce the cost of its flagship med Daraprim.
Sure, they say it’s not related to the Daraprim kerfluffle, but it certainly reflects a, shall we say, blase attitude towards ethical behavior that seems to permeate his business dealings.
Of course, he’s innocent until proven guilty, but who’s really taking the over/under on that?